Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2023-01, Vol.25 (1), p.46-55
• Main Authors: Charbonnel, Bernard H., Chen, Hungta, Cid‐Ruzafa, Javier, Cooper, Andrew, Fenici, Peter, Gomes, Marilia B., Saraiva, Gabriela L., Medina, Jesús, Nicolucci, Antonio, Shestakova, Marina V., Shimomura, Iichiro, Surmont, Filip, Tang, Fengming, Vora, Jiten, Watada, Hirotaka, Khunti, Kamlesh
• Format: Article
• Language: English
• Subjects: antidiabetic drug; Diabetes Mellitus, Type 2 - drug therapy; Glucose; glycaemic control; Glycated Hemoglobin; Humans; Life Sciences; observational study; Original; second‐line treatment; type 2 diabetes
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14842

Aims To describe glucose‐lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow‐up from the start of second‐line therapy. Materials and Methods This data analysis from the 3‐year, observational DISCOVER study programme included 14 687 participants from 37 countries with T2D initiating second‐line glucose‐lowering therapy. Treatment and HbA1c data were collected at baseline (start of second‐line therapy) and at 6, 12, 24 and 36 months. Treatment regimen changes over follow‐up were analysed using the McNemar test, with carry‐forward imputation for intermediate missing values. Results A total of 11 592 participants had treatment data at baseline and 36 months, and 11 882 had HbA1c data at baseline. At baseline and 36 months, respectively, rates of oral monotherapy use were 12.1% and 12.4% (P = 0.22), rates of dual oral therapy use were 63.4% and 47.6% (P